Based on the efficacy of EHop-016 as an inhibitor of migration and Rac1 activation, a new series of carbazole derivatives has been synthesized. Cytotoxic and anti-migratory effects of these compounds were evaluated in MCF-7 and MDA-MB-231 breast cancer cell lines. Preliminary investigations of their anticancer activity demonstrated that several compounds have moderate antiproliferative effects on cancer cell lines with GI₅₀ values in the range of 13–50 µM. Furthermore, compounds 3b and 11b inhibit migration activity of metastatic cell line MDA-MB-231 by 32% and 34%, respectively. Compound 11b was shown to inhibit activation of the Rho GTPase Rac1 by 55% at 250 nM in both MDA-MB-231 and MDA-MB-435 cell lines. Compared with the IC₅₀ of Rac1 inhibition by lead compound EHop-016 of 1.1 µM, compound 11b demonstrates 4X improved in vitro efficacy.

基于EHop-016作为迁移和Rac1激活抑制剂的功效，合成了一系列新的咔唑衍生物。在 MCF-7 和 MDA-MB-231 乳腺癌细胞系中评估了这些化合物的细胞毒性和抗迁移作用。_{对其抗癌活性的初步研究表明，几种化合物对 GI 50}值在 13–50 µM 范围内的癌细胞系具有中等抗增殖作用。此外，化合物3b和11b分别抑制转移细胞系MDA-MB-231的迁移活性32%和34%。在 MDA-MB-231 和 MDA-MB-435 细胞系中，化合物11b在 250 nM 时可抑制 Rho GTPase Rac1 的激活 55%。与先导化合物 EHop-016 的 1.1 µM Rac1 抑制作用的IC _{50相比，化合物}11b 的体外功效提高了 4 倍。